Title |
Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial
|
---|---|
Published in |
Trials, August 2014
|
DOI | 10.1186/1745-6215-15-317 |
Pubmed ID | |
Authors |
Roger Olofsson, Lars Ny, Malin Sternby Eilard, Magnus Rizell, Christian Cahlin, Ulrika Stierner, Ulf Lönn, Johan Hansson, Ingrid Ljuslinder, Lotta Lundgren, Gustav Ullenhag, Jens Folke Kiilgaard, Jonas Nilsson, Per Lindnér |
Abstract |
Uveal melanoma is the most common primary intraocular malignancy in adults. Despite successful control of the primary tumor, metastatic disease will ultimately develop in approximately 50% of patients, with the liver being the most common site for metastases. The median survival for patients with liver metastases is between 6 and 12 months, and no treatment has in randomized trials ever been shown to prolong survival. A previous phase II trial using isolated hepatic perfusion (IHP) has suggested a 14-month increase in overall survival compared with a historic control group consisting of the longest surviving patients in Sweden during the same time period (26 versus 12 months). |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 25% |
Australia | 1 | 13% |
Singapore | 1 | 13% |
Unknown | 4 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 8 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Netherlands | 1 | 2% |
Unknown | 48 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 12 | 24% |
Researcher | 7 | 14% |
Student > Bachelor | 6 | 12% |
Other | 5 | 10% |
Student > Postgraduate | 3 | 6% |
Other | 7 | 14% |
Unknown | 9 | 18% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 26 | 53% |
Biochemistry, Genetics and Molecular Biology | 3 | 6% |
Nursing and Health Professions | 2 | 4% |
Agricultural and Biological Sciences | 2 | 4% |
Neuroscience | 2 | 4% |
Other | 2 | 4% |
Unknown | 12 | 24% |